108.52
2.56 (2.42%)
| Previous Close | 105.96 |
| Open | 106.01 |
| Volume | 1,571,717 |
| Avg. Volume (3M) | 2,674,420 |
| Market Cap | 14,093,972,480 |
| Price / Sales | 14.47 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.63 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 130.00 (Morgan Stanley, 19.79%) | Buy |
| Median | 80.00 (-26.28%) | |
| Low | 67.00 (Guggenheim, -38.26%) | Buy |
| Average | 86.00 (-20.75%) | |
| Total | 16 Buy | |
| Avg. Price @ Call | 75.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 130.00 (19.79%) | Buy | 103.87 |
| BTIG | 30 Oct 2025 | 100.00 (-7.85%) | Buy | 92.41 |
| 25 Sep 2025 | 80.00 (-26.28%) | Buy | 60.18 | |
| Barclays | 30 Oct 2025 | 85.00 (-21.67%) | Buy | 92.41 |
| 02 Oct 2025 | 70.00 (-35.50%) | Buy | 61.46 | |
| Canaccord Genuity | 30 Oct 2025 | 100.00 (-7.85%) | Buy | 92.41 |
| 26 Sep 2025 | 75.00 (-30.89%) | Buy | 60.03 | |
| Citigroup | 30 Oct 2025 | 100.00 (-7.85%) | Buy | 92.41 |
| Evercore ISI Group | 30 Oct 2025 | 90.00 (-17.07%) | Buy | 92.41 |
| 07 Oct 2025 | 68.00 (-37.34%) | Buy | 63.44 | |
| UBS | 30 Oct 2025 | 110.00 (1.36%) | Buy | 92.41 |
| 25 Sep 2025 | 80.00 (-26.28%) | Buy | 60.18 | |
| Piper Sandler | 22 Oct 2025 | 90.00 (-17.07%) | Buy | 68.03 |
| Guggenheim | 25 Sep 2025 | 67.00 (-38.26%) | Buy | 60.18 |
| JP Morgan | 25 Sep 2025 | 70.00 (-35.50%) | Buy | 60.18 |
| Leerink Partners | 25 Sep 2025 | 75.00 (-30.89%) | Buy | 60.18 |
| Mizuho | 25 Sep 2025 | 70.00 (-35.50%) | Buy | 60.18 |
| Stifel | 25 Sep 2025 | 70.00 (-35.50%) | Buy | 60.18 |
| TD Cowen | 25 Sep 2025 | 72.00 (-33.65%) | Buy | 60.18 |
| Wolfe Research | 25 Sep 2025 | 75.00 (-30.89%) | Buy | 60.18 |
| Wells Fargo | 22 Sep 2025 | 72.00 (-33.65%) | Buy | 59.78 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |